Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» 80% Market Share In HIV Pharmaceutical Sector And Unappreciated Pipeline Make Gilead Sciences (GILD) A Contrarian Stock Pick From These Saint Louis Porfolio Managers
80% Market Share In HIV Pharmaceutical Sector And Unappreciated Pipeline Make Gilead Sciences (GILD) A Contrarian Stock Pick From These Saint Louis Porfolio Managers
80% Market Share In HIV Pharmaceutical Sector And Unappreciated Pipeline Make Gilead Sciences (GILD) A Contrarian Stock Pick From These Saint Louis Porfolio Managers
Submitted by
admin
on December 5, 2010 - 11:48am
Source:
Yahoo/Wall Street Transcript
News Tags:
Gilead Sciences
HIV
Headline:
80% Market Share In HIV Pharmaceutical Sector And Unappreciated Pipeline Make Gilead Sciences (GILD) A Contrarian Stock Pick From These Saint Louis Porfolio Managers
Do Not Allow Advertisers to Use My Personal information
